Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Gap Up – What’s Next?

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) gapped up prior to trading on Monday . The stock had previously closed at $4.20, but opened at $4.58. Perspective Therapeutics shares last traded at $4.53, with a volume of 275,388 shares changing hands.

Analyst Ratings Changes

CATX has been the subject of a number of research analyst reports. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday. B. Riley Financial raised their price target on Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Piper Sandler initiated coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target for the company. BTIG Research restated a “buy” rating and issued a $14.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. Finally, Truist Financial set a $12.00 price target on Perspective Therapeutics in a research report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $12.63.

Perspective Therapeutics Price Performance

The business has a 50-day moving average price of $4.77 and a two-hundred day moving average price of $3.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.17 and a quick ratio of 5.17.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The company had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. As a group, sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -1.17 earnings per share for the current fiscal year.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its position in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after purchasing an additional 5,475 shares in the last quarter. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics during the 4th quarter worth about $28,000. nVerses Capital LLC purchased a new stake in Perspective Therapeutics during the 4th quarter worth about $31,000. Engineers Gate Manager LP purchased a new stake in Perspective Therapeutics during the 4th quarter worth about $35,000. Finally, AXQ Capital LP increased its position in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after purchasing an additional 2,481 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.